The Evaluation of Uterine Sarcomas: Tertiary Center Experience
BJECTIVES: To elucidate prognostic factors, determine the best course of treatment methods, and assess oncological results in individuals diagnosed with uterine sarcoma. STUDY DESIGN: Between January 2001 and August 2023, 30 patients with uterine sarcomas (US) were included and analyzed in this c...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medical Network
2024-08-01
|
| Series: | Gynecology Obstetrics & Reproductive Medicine |
| Subjects: | |
| Online Access: | https://gorm.com.tr/index.php/GORM/article/view/1482 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823857343677333504 |
|---|---|
| author | Onur Yavuz Kadir Alper Mankan Asli Akdoner Sultan Ot Hasan Bahadir Saatli |
| author_facet | Onur Yavuz Kadir Alper Mankan Asli Akdoner Sultan Ot Hasan Bahadir Saatli |
| author_sort | Onur Yavuz |
| collection | DOAJ |
| description |
BJECTIVES: To elucidate prognostic factors, determine the best course of treatment methods, and assess oncological results in individuals diagnosed with uterine sarcoma.
STUDY DESIGN: Between January 2001 and August 2023, 30 patients with uterine sarcomas (US) were included and analyzed in this cross-sectional study. Sixteen patients (53.3%) had uterine leiomyosarcoma, 6 patients (20%) had high-grade endometrial stromal sarcoma, 8 patients (26.7%) had low-grade endometrial stromal sarcoma.
RESULTS: The median follow-up of all participants was 50 months. Recurrence was detected in 43.3% of the patients. 5-year survival ratio was 73.3%, 5-year disease-free survival ratio was 66.7%, the overall survival ratio was 70% and the overall disease-free survival rate was 56.6%. No difference was observed between groups in terms of survival comparisons. No statistically significant effect of adjuvant systemic chemotherapy, adjuvant radiotherapy, and combined treatments on median overall survival and median disease-free survival was detected (p>0.05).
CONCLUSION: Uterine sarcomas are uncommon malignancies characterized by a poor prognosis, even in early stages, and they are associated with a high recurrence ratio. The most effective treatment method remains unclear to date.
|
| format | Article |
| id | doaj-art-4c27bd4018fd436eb8a4f404012ce3f8 |
| institution | Kabale University |
| issn | 1300-4751 2602-4918 |
| language | English |
| publishDate | 2024-08-01 |
| publisher | Medical Network |
| record_format | Article |
| series | Gynecology Obstetrics & Reproductive Medicine |
| spelling | doaj-art-4c27bd4018fd436eb8a4f404012ce3f82025-02-11T21:18:38ZengMedical NetworkGynecology Obstetrics & Reproductive Medicine1300-47512602-49182024-08-0130210.21613/GORM.2023.1482The Evaluation of Uterine Sarcomas: Tertiary Center ExperienceOnur Yavuz0Kadir Alper Mankan1Asli Akdoner2Sultan Ot3Hasan Bahadir Saatli4Dokuz Eylül University School of MedicineDokuz Eylül University School of MedicineDokuz Eylül University School of MedicineVize State HospitalDokuz Eylül University School of Medicine BJECTIVES: To elucidate prognostic factors, determine the best course of treatment methods, and assess oncological results in individuals diagnosed with uterine sarcoma. STUDY DESIGN: Between January 2001 and August 2023, 30 patients with uterine sarcomas (US) were included and analyzed in this cross-sectional study. Sixteen patients (53.3%) had uterine leiomyosarcoma, 6 patients (20%) had high-grade endometrial stromal sarcoma, 8 patients (26.7%) had low-grade endometrial stromal sarcoma. RESULTS: The median follow-up of all participants was 50 months. Recurrence was detected in 43.3% of the patients. 5-year survival ratio was 73.3%, 5-year disease-free survival ratio was 66.7%, the overall survival ratio was 70% and the overall disease-free survival rate was 56.6%. No difference was observed between groups in terms of survival comparisons. No statistically significant effect of adjuvant systemic chemotherapy, adjuvant radiotherapy, and combined treatments on median overall survival and median disease-free survival was detected (p>0.05). CONCLUSION: Uterine sarcomas are uncommon malignancies characterized by a poor prognosis, even in early stages, and they are associated with a high recurrence ratio. The most effective treatment method remains unclear to date. https://gorm.com.tr/index.php/GORM/article/view/1482Endometrial stromal sarcomaLeiomyosarcomaTreatment Uterine sarcoma |
| spellingShingle | Onur Yavuz Kadir Alper Mankan Asli Akdoner Sultan Ot Hasan Bahadir Saatli The Evaluation of Uterine Sarcomas: Tertiary Center Experience Gynecology Obstetrics & Reproductive Medicine Endometrial stromal sarcoma Leiomyosarcoma Treatment Uterine sarcoma |
| title | The Evaluation of Uterine Sarcomas: Tertiary Center Experience |
| title_full | The Evaluation of Uterine Sarcomas: Tertiary Center Experience |
| title_fullStr | The Evaluation of Uterine Sarcomas: Tertiary Center Experience |
| title_full_unstemmed | The Evaluation of Uterine Sarcomas: Tertiary Center Experience |
| title_short | The Evaluation of Uterine Sarcomas: Tertiary Center Experience |
| title_sort | evaluation of uterine sarcomas tertiary center experience |
| topic | Endometrial stromal sarcoma Leiomyosarcoma Treatment Uterine sarcoma |
| url | https://gorm.com.tr/index.php/GORM/article/view/1482 |
| work_keys_str_mv | AT onuryavuz theevaluationofuterinesarcomastertiarycenterexperience AT kadiralpermankan theevaluationofuterinesarcomastertiarycenterexperience AT asliakdoner theevaluationofuterinesarcomastertiarycenterexperience AT sultanot theevaluationofuterinesarcomastertiarycenterexperience AT hasanbahadirsaatli theevaluationofuterinesarcomastertiarycenterexperience AT onuryavuz evaluationofuterinesarcomastertiarycenterexperience AT kadiralpermankan evaluationofuterinesarcomastertiarycenterexperience AT asliakdoner evaluationofuterinesarcomastertiarycenterexperience AT sultanot evaluationofuterinesarcomastertiarycenterexperience AT hasanbahadirsaatli evaluationofuterinesarcomastertiarycenterexperience |